» Articles » PMID: 36335094

Ferroptosis: a Double-edged Sword Mediating Immune Tolerance of Cancer

Overview
Journal Cell Death Dis
Date 2022 Nov 6
PMID 36335094
Authors
Affiliations
Soon will be listed here.
Abstract

The term ferroptosis was put forward in 2012 and has been researched exponentially over the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed cell death, which belongs to a type of necrosis and is distinguished from apoptosis and autophagy. Actuated by iron-dependent phospholipid peroxidation, ferroptosis is modulated by various cellular metabolic and signaling pathways, including amino acid, lipid, iron, and mitochondrial metabolism. Notably, ferroptosis is associated with numerous diseases and plays a double-edged sword role. Particularly, metastasis-prone or highly-mutated tumor cells are sensitive to ferroptosis. Hence, inducing or prohibiting ferroptosis in tumor cells has vastly promising potential in treating drug-resistant cancers. Immunotolerant cancer cells are not sensitive to the traditional cell death pathway such as apoptosis and necroptosis, while ferroptosis plays a crucial role in mediating tumor and immune cells to antagonize immune tolerance, which has broad prospects in the clinical setting. Herein, we summarized the mechanisms and delineated the regulatory network of ferroptosis, emphasized its dual role in mediating immune tolerance, proposed its significant clinical benefits in the tumor immune microenvironment, and ultimately presented some provocative doubts. This review aims to provide practical guidelines and research directions for the clinical practice of ferroptosis in treating immune-resistant tumors.

Citing Articles

ENQUIRE automatically reconstructs, expands, and drives enrichment analysis of gene and Mesh co-occurrence networks from context-specific biomedical literature.

Musella L, Afonso Castro A, Lai X, Widmann M, Vera J PLoS Comput Biol. 2025; 21(2):e1012745.

PMID: 39932993 PMC: 11844901. DOI: 10.1371/journal.pcbi.1012745.


Epigenetic regulation of targeted ferroptosis: A new strategy for drug development.

Ouyang S, Zeng Z, He J, Luo L J Pharm Anal. 2025; 14(10):101012.

PMID: 39850234 PMC: 11755343. DOI: 10.1016/j.jpha.2024.101012.


Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells.

Zhang Z, Xu H, He J, Hu Q, Liu Y, Xu Z Cell Death Dis. 2025; 16(1):28.

PMID: 39827156 PMC: 11743205. DOI: 10.1038/s41419-025-07330-8.


Global research trends and frontiers in ferroptosis in hepatocellular carcinoma: a bibliometric and visualization study.

Ning L, Chen D, Han J, Xie G, Sun J Front Oncol. 2024; 14:1474496.

PMID: 39723378 PMC: 11668663. DOI: 10.3389/fonc.2024.1474496.


Overexpression of ELF3 in the PTEN-deficient lung epithelium promotes lung cancer development by inhibiting ferroptosis.

Yuan Z, Han X, Xiao M, Zhu T, Xu Y, Tang Q Cell Death Dis. 2024; 15(12):897.

PMID: 39695109 PMC: 11655876. DOI: 10.1038/s41419-024-07274-5.


References
1.
Drijvers J, Gillis J, Muijlwijk T, Nguyen T, Gaudiano E, Harris I . Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8 T Cells. Cancer Immunol Res. 2020; 9(2):184-199. PMC: 7864883. DOI: 10.1158/2326-6066.CIR-20-0384. View

2.
Lipson E, Vincent J, Loyo M, Kagohara L, Luber B, Wang H . PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2014; 1(1):54-63. PMC: 3885978. DOI: 10.1158/2326-6066.CIR-13-0034. View

3.
Sugiura A, Rathmell J . Metabolic Barriers to T Cell Function in Tumors. J Immunol. 2018; 200(2):400-407. PMC: 5777533. DOI: 10.4049/jimmunol.1701041. View

4.
Burnstock G, Di Virgilio F . Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540. PMC: 3889385. DOI: 10.1007/s11302-013-9372-5. View

5.
Demuynck R, Efimova I, Naessens F, Krysko D . Immunogenic ferroptosis and where to find it?. J Immunother Cancer. 2021; 9(12). PMC: 8671998. DOI: 10.1136/jitc-2021-003430. View